Document Actions
Fornix sells Dutch Allergy Division to ALK-Abelló
Fornix is planning to sell its Dutch Allergy Division to ALK-Abelló. The only condition precedent to which the transaction remains subject is shareholders’ approval.
Following a strategic re-orientation for the Dutch activities of its Allergy Division (Artu Biologicals), Fornix BioSciences announces that it has signed a Share Purchase Agreement with ALK-Abelló regarding the sale of 100% of the shares in the Dutch Allergy Division for a purchase price of EUR 19.6 million in cash. The transaction is intended to become effective on 1 July 2010.
As part of the proposed transaction, all employees, assets and activities currently part of the Dutch Allergy Division will be transferred as per that date. This transfer will include Fornix Chief Scientific Officer Dr. Folkert F. Roossien. The German activities incorporated in Artu Biologicals Deutschland will not be part of the proposed transaction.
ALK, the world leader within allergy immunotherapy, is a research-driven global pharmaceutical company focusing on allergy treatment, prevention and diagnosis. ALK is already present in the Netherlands and now strengthens its market position as a result of the proposed transaction. ALK is committed to expanding the combined activities to create a leading platform within allergy immunotherapy in the Netherlands.
